Arcadia Biosciences

Q2 FY2026 EarningsQ2 FY26 results missed consensus on the top line but saw significant GAAP EPS underperformance due to non-cash valuation adjustments. Revenue of $1.44M fell -24.05% short of the $1.90M consensus, primarily due to Zola® inventory shortages and shipping delays. Despite a -41% YoY widening of net loss attributable to common stockholders to $6.27M, management highlighted a positive inflection point in July/August sales and a drastically improved cash burn rate ($319K used in ops).